propiverine has been researched along with Prostatic Hyperplasia in 9 studies
propiverine: anticholinergic used for overactive bladder syndrome
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (alpha(1)-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB)." | 9.14 | Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. ( Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T, 2009) |
| "The efficacy and safety of additional administration of propiverine were prospectively studied for naftopidil-resistant nocturia in patients with benign prostatic hypertrophy (BPH)." | 7.77 | [Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy]. ( Hashimoto, Y; Hatakeyama, S; Kamimura, N; Kawaguchi, T; Koie, T; Kudo, S; Ohyama, C; Takahashi, S; Yoneyama, T; Yoshikawa, K, 2011) |
| "Although the anticholinergic dosage was low, the present results suggest that naftopidil monotherapy was as useful as combination therapy of naftopidil and an anticholinergic agent." | 6.72 | Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. ( Hanazawa, K; Honda, S; Kawachi, Y; Koizumi, K; Maruyama, O; Noto, K; Saitoh, T; Sugimura, S; Sugiyama, Y; Yamashita, R, 2006) |
| "Naftopidil is an alpha-blocker (AB) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting." | 6.58 | Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. ( Dahm, P; Gandhi, S; Hwang, EC; Imamura, M; Jung, JH; Kim, MH; Pang, R, 2018) |
| "To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (alpha(1)-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB)." | 5.14 | Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. ( Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T, 2009) |
| "The efficacy and safety of additional administration of propiverine were prospectively studied for naftopidil-resistant nocturia in patients with benign prostatic hypertrophy (BPH)." | 3.77 | [Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy]. ( Hashimoto, Y; Hatakeyama, S; Kamimura, N; Kawaguchi, T; Koie, T; Kudo, S; Ohyama, C; Takahashi, S; Yoneyama, T; Yoshikawa, K, 2011) |
| "Although the anticholinergic dosage was low, the present results suggest that naftopidil monotherapy was as useful as combination therapy of naftopidil and an anticholinergic agent." | 2.72 | Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. ( Hanazawa, K; Honda, S; Kawachi, Y; Koizumi, K; Maruyama, O; Noto, K; Saitoh, T; Sugimura, S; Sugiyama, Y; Yamashita, R, 2006) |
| "Naftopidil is an alpha-blocker (AB) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting." | 2.58 | Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. ( Dahm, P; Gandhi, S; Hwang, EC; Imamura, M; Jung, JH; Kim, MH; Pang, R, 2018) |
| "All of the male patients had benign prostatic hyperplasia (BPH), and all of the female patients had overactive bladder (OAB)." | 1.35 | Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder. ( Kadekawa, K; Miyazato, M; Mukouyama, H; Nishijima, S; Sugaya, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hwang, EC | 1 |
| Gandhi, S | 1 |
| Jung, JH | 1 |
| Imamura, M | 1 |
| Kim, MH | 1 |
| Pang, R | 1 |
| Dahm, P | 1 |
| Matsukawa, Y | 1 |
| Takai, S | 1 |
| Funahashi, Y | 1 |
| Kato, M | 1 |
| Yamamoto, T | 1 |
| Gotoh, M | 1 |
| Yokoyama, T | 1 |
| Uematsu, K | 1 |
| Watanabe, T | 1 |
| Sasaki, K | 1 |
| Kumon, H | 1 |
| Nagai, A | 1 |
| Sugaya, K | 1 |
| Nishijima, S | 1 |
| Kadekawa, K | 1 |
| Miyazato, M | 1 |
| Mukouyama, H | 1 |
| Kamimura, N | 1 |
| Hatakeyama, S | 1 |
| Kudo, S | 1 |
| Yoneyama, T | 1 |
| Hashimoto, Y | 1 |
| Koie, T | 1 |
| Yoshikawa, K | 1 |
| Kawaguchi, T | 1 |
| Takahashi, S | 1 |
| Ohyama, C | 1 |
| Lee, KS | 1 |
| Choo, MS | 1 |
| Kim, DY | 1 |
| Kim, JC | 1 |
| Kim, HJ | 1 |
| Min, KS | 1 |
| Lee, JB | 1 |
| Jeong, HJ | 1 |
| Lee, T | 1 |
| Park, WH | 1 |
| Athanasopoulos, A | 1 |
| Perimenis, P | 1 |
| Maruyama, O | 1 |
| Kawachi, Y | 1 |
| Hanazawa, K | 1 |
| Koizumi, K | 1 |
| Yamashita, R | 1 |
| Sugimura, S | 1 |
| Honda, S | 1 |
| Sugiyama, Y | 2 |
| Saitoh, T | 1 |
| Noto, K | 1 |
2 reviews available for propiverine and Prostatic Hyperplasia
| Article | Year |
|---|---|
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Benzilates; Drug Combinations; Ethamsylate; Humans; Indoles; Lower Uri | 2018 |
Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Benzhydryl Compounds; Benzila | 2005 |
4 trials available for propiverine and Prostatic Hyperplasia
3 other studies available for propiverine and Prostatic Hyperplasia
| Article | Year |
|---|---|
Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder.
Topics: Adenosine Triphosphate; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Benzi | 2009 |
[Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Benzilates; Cholinergic Antagonists; Drug Res | 2011 |
[Parkinsonism induced by propiverine hydrochloride--report of 3 cases].
Topics: Aged; Aged, 80 and over; Benzilates; Cholinergic Antagonists; Gait; Humans; Male; Parasympatholytics | 1997 |